456 results about "L-Aspartic acid" patented technology

A composition and associated method for chemical mechanical planarization (or other polishing) are described which afford high tantalum to copper selectivity in copper CMP and which are tunable (in relation to polishing performance). The composition comprises an abrasive and an N-acyl-N-hydrocarbonoxyalkyl aspartic acid compound and/or a tolyltriazole derivative.

The invention discloses an enzyme conversion method for preparing gamma-butyric acid. The preparation method comprises employing two mixed acidic amino acids of L-glutamic acid and L-aspartic acid as raw material, mixing the cells of Escherichia.coli AS1.505 with highly active L-glutamic acid decarboxylases and the conversion liquid containing the mixture of L-glutamic acid and L-aspartic acid, implementing enzymatic reaction under the temperature of 28~45íµ, then separating the conversion products by isoelectric point crystallization process or isoelectric point crystallization and ion exchange resin combined method to obtain high purity gamma-butyric acid and L-aspartic acid. The invention solves the problem of the highly effective separation of two acidic mixed amino acids, and obtains gamma-butyric acid with higher additional value, and has advantages of low price, simple operation, short conversion time, and low production cost.

The invention provides genetic engineering bacteria for producing beta-alanine. The genetic engineering bacteria are obtained by the following method of amplifying L-aspartic acid alpha-decarboxylase gene panD of a donor containing panD gene by PCY, cloning the panD to a plasmid capable of expressing a foreign gene at high efficiency to obtain a vector for abundant expression of the panD gene, and transforming the vector into a receiver to obtain the genetic engineering bacteria for producing beta-alanine. The genetic engineering bacteria and preparation and application thereof have the main advantages that (1) the engineering bacteria of beta-alanine can be synthesized by the preparation of Escherichia coli; (2) the engineering bacteria has high ability in synthesizing beta-alanine, and the primary study determines that the synthesis ability is up to 2.94 g/l and that the beta-alanine is unlikely be determined by an identical method using a starting strain; and (3) the Escherichia coli is improved by using genetic engineering technology to achieve definite breeding target and high efficiency.

The invention provides therapeutic methods and products for the treatment of inflammation, inflammatory diseases and conditions, and proliferative diseases and conditions. The invention also provides methods and products for inhibiting inflammation in excised cells, tissues and organs. The invention further provides oral care methods and products for the treatment of the tissues of an animal's mouth. Finally, the invention provides personal care methods and products for the treatment of the skin of an animal. All of these methods and products utilize N-acyl-L-aspartic acid or an ester or pharmaceutically-acceptable salt thereof.

A compound represented by the following general formula (I), wherein R¹ and R² represent a hydrocarbon group having 1 to 26 carbon atoms, preferably a linear or branched alkyl group, R³ represents a hydrocarbon group having 7 to 10 carbon atoms, preferably a linear or branched alkyl group, n represents 1 or 2 provided that the acidic amino acid residue in the molecule is L-aspartic acid residue when n is 1 and said acidic amino acid residue is L-glutamic acid residue when n is 2, and a gelling agent for an oil comprising said compound

The invention discloses a preparing method of bifidobacteria bacterial active agent and single-purpose protecting agent, which is characterized by the following: allocating 0.01-5.0 wt glycerin, 0.1-6.0 wt polyvinyl pyrrolidon, 0.1-5.0 carbowax, 1.0-10.0 wt skimmed milk powder, 0.5-15.0 wt mycose, 0.1-5.0 wt glutavene, 0.1-5.0 wt L-aspartic acid, 0.1-5.0 wt vitamin C sodium and 0.1-5.0 wt ornithine hydrochlorate. This invention solves the problem of preservation difficulty at normal temperature with conventional method.

The invention discloses a two-block copolymer of poly-N-isopropyl acrylamide-polyamino acid and making method, which is characterized by the following: the number average molecular weight of poly-N-isopropyl acrylamide-polyamino acid is 1000-10000; the polyamino acid is poly-L-glutamic acid or poly-L-aspartic acid with number average molecular weight at 1000-30000; the molar percentage of amino acid carbobenzoxy is 0-90%; the invention uses hydrogen bromide or reducing method to strip benzyl through catalyzing and hydrogenating to obtain the product, which possesses double response for temperature and pH value in the solution; the copolymer can be biological decomposed to be discharged out of body through kidney directly, which can be carrier of target drug release and injectable intellectual response aquagel.

The present application provides a wild type phosphatidylcholine specificity phospholipase C (PLC) mutant of Bacillus cereus, the related mutations comprising asparagine at position 63 mutating to another amino acid; also comprising mutation of arginine to histidine at position 20 and of alanine to aspartic acid at position 83. The present application also provides a nucleic acid molecule encoding said mutant, a vector containing said nucleic acid molecule, and a cell containing said nucleic acid molecule or vector. The present application also provides uses of said mutant, nucleic acid molecule vector, and cell.

A method of making an alternative bottled water comprising as main ingredients, D-ribose, L-carnitine, Coenzyme Q10, Adenosine triphosphate, Taurine, Garcinia combgia, Chromium polynicotinate, or chromium picolate with or without L-Aspartic acid to provide cardiovascular fitness and overall physical energy. Said energy fitness water may also contain a non-nutritive or nutritive sweetener, aroma and coloring. The bottled water prepared from these ingredients has pH range from 3.5 to 7.0 dependent on processing and packaging of the bottled water.

The invention discloses a novel method for synthesizing sitagliptin phosphate and a derivative thereof. The method has the advantages of readily-available raw materials, mild reaction condition, no need of using very expensive catalyst, easy control over optical purity and the like. In the novel method for synthesizing sitagliptin phosphate and the derivative thereof, L-aspartic acid is taken as a raw material, and the chemical reaction steps of amino protection, esterification, reduction, iodination or bromination, coupling, hydrolysis, acylation ammoniation, removal of protecting groups andsalt formation are performed to obtain a sitagliptin phosphate chiral salt and a hydrate thereof. The method comprises the following specific steps of: performing amino protection, esterification, reduction and iodination on L-aspartic acid serving as the raw material to obtain a compound A shown as a formula I; undergoing a coupling reaction on the compound A and a compound B shown as a formula II to obtain a compound C shown as a formula III; and performing hydrolysis, acylation ammoniation, removal of protecting groups and a salt-forming reaction on the compound C to obtain a sitagliptin phosphate hydrate.

The invention discloses preparation of a lanthanide metal-organic framework material and a method for visually assaying chiral enantiomers. The steps are as follows: (1) Ln(NO3)3.6H2O and organic ligands are taken and mixed, N,N-dimethylformamide, ethanol and water are then added, a mixed solution is formed after uniform mixing and dissolution; Ln(NO3)3.6H2O is prepared from Tb(NO3)3.6H2O and Eu(NO3)3.6H2O, and the organic ligands include 1,3,5-benzenetricarboxylic acid and L-aspartic acid; (2) the mixed solution is heated by microwaves to react, and is then cooled to room temperature, so that a turbid solution is obtained; (3) the turbid solution obtained in step (2) is centrifuged, a centrifuged product is sequentially washed with N,N-dimethylformamide and methanol and then is centrifuged again, and after the centrifuged product is dried under vacuum, the lanthanide metal-organic framework material is obtained. The prepared LOFs material can realize the visualized assay of the enantiomers; moreover, with the fluorescence properties of two types of lanthanide elements, i.e. Tb and Eu, the lanthanide metal-organic framework material can provide a broad visualized fluorescence color gamut, consequently, the application range is broadened, and the accuracy of assay is increased.

The invention discloses a chiral MOF-graphene hybrid material, a preparation method thereof, and the application of the chiral MOF-graphene hybrid material to the detection of chiral drug enantiomers, and belongs to the technical fields of nanometer composite materials, macromolecule-based composite materials, graphene-based composite materials and chiral sensing detection. The method comprises the following main steps: blending an alkaline aqueous solution of L-aspartic acid and an aqueous solution of cupric nitrate-graphene oxide, adding an ethanol solution of 4, 4'-bipyridine, leaving the mixture to stand over a night, performing centrifugal separation, washing and drying, so as to obtain the chiral MOF-graphene hybrid material. A chiral MOF-graphene hybrid material sensor constructed through the hybrid material is applied to the sensitive detection of the contents of R-2-amino-3-phenylpropionic acid and S-2-amino-3-phenylpropionic acid enantiomers.

A process for preparing high-molecular polyaspartic acid includes such steps as mixing aspartic acid with catalyst, polycondensating reaction, grinding, sieving, polycondensating reaction and grinding again, washing until it becomes neutral, and drying. It can be used as the scale-inhibiting disperser for cooling water, fertilizer synergist, etc.

The invention relates to an ornithine aspartate compound and a novel method thereof. L-aspartic acid and L-ornithine acetate are used as starting materials. The method comprises the following steps of: removing ammonium acetate serving as an intermediate product through solubility differences of ornithine and the ammonium acetate in acetone to obtain free alkali of the ornithine; and reacting thefree alkali with the L-aspartic acid to generate the ornithine and aspartate compound. The synthetic method of the ornithine and aspartate compound has the advantages of low cost, simple process, high purity of the obtained product and easy industrial production.

The invention provides a drug carrier system. The drug carrier system comprises a pH sensitive shielding system, a cation carrier and electronegative drugs, wherein the pH sensitive shielding system is a copolymer of hyperbranched polyethyleneimine, lysine and glutamic acid or the copolymer of hyperbranched polyethyleneimine, lysine and aspartic acid; in the copolymer of the hyperbranched polyethyleneimine, lysine and glutamic acid, the molar ratio of the glutamic acid to the lysine is (1.5-50):1; in the copolymer of the hyperbranched polyethyleneimine, lysine and aspartic acid, the molar ratio of the aspartic acid to the lysine is (1.5-50):1; and the weight ratio of the pH sensitive shielding system to the cation carrier is (0.5-100):1. The drug carrier system has pH value responsibility and obvious difference of cytotoxicity under different pH conditions and can be used for intelligently releasing drugs.

The invention discloses a formula for supplementing nutrients of bone and improving functions of bone and a preparation method. The formula comprises the following components in percentage by mass: 30to 70% of bone collagen protein peptide powder, 1 to 10% of L-aspartic acid calcium, 1 to 10% of hydrolyzed II-type collagen, 1 to 10% of casein phosphopeptide powder, 1 to 10% of milk minerals, and0.0002 to 0.005% of vitamin D. The formula has the advantages that according to the cause of bone diseases, several kinds of pure animals and plants are used as the raw materials and are reasonably compounded and scientifically proportioned, so that while the content of calcium in a human body is supplemented, the bone collagen protein is supplemented, and the full absorbing of calcium is accelerated; after the formula is taken for a long time, the demand and intake amount of calcium by the human body can be adjusted, and the formula is especially suitable for patients with osteoporosis or arthritis; any side or toxic effect is avoided, the auxiliary treatment effect is realized on treatment of various bone diseases, the nutrients of the bone can be supplemented, the functions of the bonecan be improved, and the functions of enhancing the immunity of the human body, resisting the aging and resisting the fatigue are realized.

Manufacture or use of a mutant prenyl diphosphate synthase in which the amino acid residue located at the fifth position in the N-terminal direction from D of the N-terminal of the aspartic acid-rich domain DDXX(XX)D (the two X's in the parentheses may not be present) present in the second region among the conserved regions of the prenyl diphosphate synthase has been substituted by another amino acid.

The invention provides a polyaspartic acid derivative synthetic method. The method comprises the following steps: monosaccharide or disaccharide and monochloro acetic acid are reacted under catalysisof NaOH, and a reactant is subjected to further acidifying and purification to obtain carboxymethyl saccharide; carboxymethyl saccharide and diamine are subjected to dehydration condensation under catalysis of phosphoric acid to obtain glycosyl acetyl diamine; L-aspartic acid and phosphoric acid are respectively added in a kneading reactor for mixing, a mixture is stirred and heated, polymerization is carried out for preset time to obtain polysuccinimide; glycosyl acetyl diamine is added in a reaction vessel of polysuccinimide for a reaction, polysuccinimide is subjected to ring-opening and grafting reaction to obtain a polysuccinimide derivative; the polysuccinimide derivative is added in a hydrolysis kettle, an aqueous solution of alkali is add drop by drop, a hydrolysis reaction is carried out, and a liquid-phase product after hydrolysis is a glycosyl acetyl diamine-grafted modified polyaspartate aqueous solution. The synthetic method is simple and easy to operate, a grafting modification step and a polymerization step are coupled, so that the side-chain grafting rate is increased and the polymericular weight can be regulated and controlled.

The invention discloses a health-care food composition with a physical fatigue relieving function and an immunity enhancing function. A formula of the health-care food composition comprises the following components in parts by weight: 12 parts of guarana extract, 3 parts of root of American ginseng extract, 83 parts of taurine, 5 parts of L-isoleucine, 1.25 parts of L-leucine, 2.5 parts of L-valine, 0.02 part of L-tryptophan, 0.02 part of L-phenylalanine, 0.02 part of L-threonine, 0.02 part of L-methionine, 1 part of L-lysine hydrochloride, 1 part of L-aspartic acid, 12 parts of glycine, 12 parts of L-alanine and 80 parts of white kidney bean extract. A preparation containing the health-care food composition disclosed by the invention can be a beverage, a capsule, a tablet, a chewable tablet, a granular formulation, an oral solution, a soft capsule, paste, flowing liquid and semi-flowing liquid. A health-care product disclosed by the invention adopts a low-sugar formula and the intake of human bodies to sugar can be reduced; meanwhile, the absorption of people on starch substances in daily diet can be inhibited, so that risks of diseases including blood glucose, blood pressure, obesity and the like are reduced.